METHODS Sixty patients (45 men (75%), 55 AE 7 years) with a documented single vessel type A or B1 lesion, either stable or unstable angina without biochemical signs of myocardial infarction, were included in this single blind randomized clinical trial. Patients were randomized to implantation of a DES or BVS (Xience Prime or ABSORB, respectively) in a one-to-one fashion. Approximately 1 month after percutaneous coronary intervention patients underwent H215O PET to assess (hyperemic) MBF, cold pressor test MBF, and CFR.
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BACKGROUND The safety and performance of the current Absorb Bioresorbable Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa Clara, CA) has been previously established in 101 patients enrolled in the Cohort B of the First-in-Man ABSORB trial. At 48 months, MACE rate in Cohort B was 10.1%, with no scaffold thrombosis (ST) reported. ABSORB EXTEND was initiated as a global, continued access, international (outside of the US) study to expand the clinical experience with the Absorb BVS to different geographies. Of note, investigators were allowed to treat patients with longer coronary lesions and smaller vessels than those in the Cohort B trial, using either longer scaffold lengths or planned overlap with the 2.5-mm and 3.0-mm Absorb BVS.
METHODS ABSORB EXTEND is a prospective, single-arm, open-label clinical study that enrolled 812 subjects at 56 sites. Included were patients with lesions 28 mm in length and reference vessel diameter of 2.0 mm -3.3 mm (as assessed by on-line QCA or IVUS). Treatment of a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel, was permitted.
RESULTS Interim 24-month data in the first 450 ABSORB EXTEND study patients has been previously presented. Among patients included, 33% had unstable angina, 29% prior MI and 27% diabetes mellitus. Mean RVD and mean lesion length were 2.61AE0.35 mm and 11.61AE4.89 mm, respectively. In these 450 patients, hierarchical MACE, TVF and def/prob ST rates at 2 years were 6.7%, 7.4% and 1.1%, respectively. Long-term (36-month) follow-up data will be presented for the first 500 patients enrolled with the aim of providing substantial data on long-term safety and performance of the Absorb BVS in a larger population of patients, including those with planned overlapping and dual vessel treatment.
CONCLUSIONS Long-term outcomes in approximately 500 patients at 36 months (the largest patient cohort reported at this time point to date) from ABSORB EXTEND will provide further insight into the safety and performance of the Absorb BVS. BACKGROUND The aim of this single center observational study was to investigate the feasibility of bioresorbable vascular scaffold (BVS) in treatment in-stent restenosis lesions. In stent restenosis is still a relatively common problem in daily practice. Existing solutions were not fully effective so far. The use of drug-eluting stents (DES) is related with increased thrombosis risk, also drug-eluting balloon has disadvantage because the eluted-drug stays in the arterial wall only for few weeks, which is not sufficient to eliminate the risk of restenosis. Bioresorbable scaffolds could be possible solution of this issue. The BVS has a number of proposed advantages over current metallic stent technology which could be helpful in providing short-term vessel scaffolding and capability of prolonged drug delivery.
METHODS Between October 2013 and January 2015, 53 Patients (61 lesions) were enrolled in single arm prospective open label study in which in stent restenosis lesions was suitable for BVS implantation. Primary endpoints were procedural success of deployment of the BVS at the target lesion and absence of in-hospital major adverse events (death, Q-wave myocardial infarction, stroke or any repeat target lesion revascularization). The mean patient age was 64AE12 years and 78% patients were male, 93% suffered from hypertension and 31% from diabetes. PCI procedures were performed in 87% patients presenting with stable CAD and 13% with acute coronary syndrome. According to the angiographic ISR pattern 45% lesions were focal and 55% were diffuse, the majority of the lesions was post DES ISR (79%). Procedural OCT evaluation was performed in all lesions (100%) before and post-BVS implantation. Estimate the size of the BVS was made on the basis of the IVUS examination just after first balloon predilatation. Lesion pre-dilatation was mandatory and post dilatation was needed in 92% of cases. After 6 month of BVS implantation clinical evaluation was made, the next 6 month patients had performed control angiography with OCT.
RESULTS Procedural success was obtained in all cases. No in-hospital clinical events and intra-procedural or acute BVS-in-stent thrombosis were reported. Mean BVS implanted length was 30,5 mm. A number of 1.6 stents were implanted per lesion. At a median of 6 months follow up 2 clinically-driven TLR ( 3.8% per patient) were reported due to recurrent ISR at the BVS-in-stent implantation site. No cardiac death, Q-wave MI occurred at follow-up. Re-evaluation by angiography with OCT will be obtained in next 12 months follow-up after procedure.
CONCLUSIONS The results of our study suggest that BVS is safe and technically feasible for the treatment of ISR in patients presenting with both stable CAD and ACS with reasonable midterm outcomes. Moreover, follow-up revealed a very low rate of adverse events in patients treated by BVS implantation in the context of treatment of instent restenosis. 
